X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

Molecular Cancer

期刊標題檢索 MOL CANCER 最新評論: The editor-in-chief of MC has many articles written by Chinese people... (2024-10-06)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[Molecular Cancer]您好,您是該頁面的第 318283 位訪客。

期刊簡介
期刊名稱Molecular Cancer Molecular Cancer
LetPub Score
8.5
52 ratings
Rate

Reputation
8.6

Influence
8.3

Speed
8.7

期刊簡稱MOL CANCER
ISSN1476-4598
h-index103
CiteScore
CiteScoreSJRSNIPCiteScore Rank
54.908.2224.737
Subject fieldQuartilesRankPercentile
Category: Biochemistry, Genetics and Molecular Biology
Subcategory: Molecular Medicine
Q12 / 178
Category: Biochemistry, Genetics and Molecular Biology
Subcategory: Cancer Research
Q13 / 230
Category: Biochemistry, Genetics and Molecular Biology
Subcategory: Oncology
Q17 / 404

自引率 (2023-2024)2.20%自引率趨勢
掲載範囲
Molecular Cancer promotes the exchange of ideas, concepts and findings in any area of cancer and related biomedical science, from a molecular point of view. Molecular Cancer is interested in articles from basic, translational and clinical research, opening new avenues for the understanding, prevention, diagnosis and treatment of cancer. Topics of interest include, but are not limited to: cell and tumor biology, angiogenesis, animal models, metastasis, cancer antigens and the immune response to them, cellular signalling and molecular biology, epidemiology, genetic and molecular profiling of cancer and molecular targets, cancer stem cells, DNA damage and repair, cell cycle, apoptosis, molecular virology and vaccine- and antibody-based cancer therapies.
官方網站http://molecular-cancer.biomedcentral.com
在線稿件提交https://submission.nature.com/new-submission/12943/3
開放訪問Yes
出版商BioMed Central
主題領域医学
出版國/地區ENGLAND
發行頻率月刊
創刊年2002
每年文章數165每年文章數趨勢
黃金OA百分比100.00%
OA Related Info
APC: Yes( EUR3990; USD4890; GBP3490; )
APC waiver:Check Notes
Other charges: No
Keywords: oncology、tumour biology、cancer antigens
Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review
Web of Science 四分位
2023-2024
WOS Quartile: Q1

CategoryEditionJIF QuartileJIF RankingJIF Percentage
BIOCHEMISTRY & MOLECULAR BIOLOGYSCIEQ14/313
ONCOLOGYSCIEQ110/322
索引 (SCI or SCIE)Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1476-4598%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: Average 2 Month(s)
競爭力 *來自作者的數據: About 50%
參考鏈接
相關期刊 【Molecular Cancer】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    NATURE MEDICINEH-index: 497

    CiteScore: 100.90
    CELLH-index: 705

    CiteScore: 110.00
    Molecular PlantH-index: 85

    CiteScore: 37.60
    NUCLEIC ACIDS RESEARCHH-index: 452

    CiteScore: 27.10
    Molecular CellH-index: 356

    CiteScore: 26.00
    PROGRESS IN LIPID RESEARCHH-index: 132

    CiteScore: 24.50
    TRENDS IN MICROBIOLOGYH-index: 172

    CiteScore: 25.30
    CELL DEATH AND DIFFERENTIATIONH-index: 193

    CiteScore: 24.70
    Nature Chemical BiologyH-index: 182

    CiteScore: 23.90
    TRENDS IN MOLECULAR MEDICINEH-index: 160

    CiteScore: 24.60
    學科內最受檢索的期刊 頁面查看次數
    International Journal of Biological Macromolecules1751994
    FASEB JOURNAL724615
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS659025
    NUCLEIC ACIDS RESEARCH555258
    JOURNAL OF BIOLOGICAL CHEMISTRY399559
    International Journal of Biological Sciences309535
    CELL302917
    GENETICS AND MOLECULAR RESEARCH257600
    ONCOGENE237152
    PLANT SCIENCE232200
  •  

    Molecular Cancer Molecular Cancer
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    4    5    6    7    8    9    10    下一頁    末頁  (頁
/40)
  [Molecular Cancer] 的評論撰寫評論
作者: 大力冰可


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-09-24 12:55:41 評論於
Strongly agree. It is true that some articles in Molecular Cancer are not of high quality, but at the very least they do not manipulate Impact Factors like some domestic journals. To put it plainly, it's still some units having double standards – wanting to publish high-scoring articles while avoiding performance evaluations. Just take a look at which units are constantly playing with the so-called blacklist to set the tone. Doesn't Tsinghua University or the Chinese Academy of Sciences still have people publishing in Molecular Cancer? Do those who truly focus on research every day really think about composing blacklists?
(0) 讚! | 大力冰可

作者: Miriam Franklin


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-09-24 09:37:48 評論於
Should we hurry up this status as well? ?
(0) 讚! | Miriam Franklin

作者: Sara Lincoln


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-09-23 18:05:42 評論於
Is this so efficient that it does not fit within the scope of the magazine?
(0) 讚! | Sara Lincoln

作者: 震山今雨


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-09-22 20:35:40 評論於
MOLECULAR CANCER is on alert, while those Chinese SCI journals with skyrocketing scores are clearly fake. Why are they not being warned? Definitely they are afraid, after all, they are all full of ****, including academicians who publish in these high scoring but fake Chinese SCI journals
(0) 讚! | 震山今雨

作者: 深渊兰芳


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-09-22 18:19:14 評論於
Review speed: 3.0 | Submission hit rate: 50.0 Emphasized research direction: Tumor; Tumor biology Experience sharing: The latest publication by Director Wang Liang from the First Hospital of the Armed Police General Hospital, Malignant clonal evolution drives multiple myeloma cellular ecological diversity and microenvironment reprogramming, looks very good. At least it has broken away from the routine articles full of circRNA in the past. I feel that the editor-in-chief of Molecular Cancer has realized the problem and is starting to turn things around
(0) 讚! | 深渊兰芳

作者: Edison Springhall


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-09-20 21:25:34 評論於
The submission has been 45 days so far, and we have only received one reviewer report
(0) 讚! | Edison Springhall

作者: Edison Springhall


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-09-20 14:49:01 評論於
I am currently 45 days old
(0) 讚! | Edison Springhall

作者: 雾都颖昕


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-09-18 21:44:49 評論於
Rejected in 2 days
(0) 讚! | 雾都颖昕

作者: Miriam Franklin


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-09-17 23:54:03 評論於
Is it the same situation for brothers? Is there any news?
(0) 讚! | Miriam Franklin

作者: Sara Lincoln


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-09-17 19:25:53 評論於
Main research focus: Tumors; experience sharing on angiogenesis: submitted for three days, always editor appointed, how long will this state last, what will be the next step ?
(0) 讚! | Sara Lincoln

作者: Edison Springhall


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-09-13 19:04:07 評論於
How is it going?
(0) 讚! | Edison Springhall

作者: Lucy Larkin


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-09-11 18:03:16 評論於
What you observe is likely an illusion
(0) 讚! | Lucy Larkin

作者: Edison Springhall


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-09-07 17:45:29 評論於
What is your status right now?
(0) 讚! | Edison Springhall

作者: 凌霄迎波


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-09-07 11:48:08 評論於
What I did is really special and functional. It is particularly evident in animal experiments
(0) 讚! | 凌霄迎波

作者: 元魁来了


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-09-04 11:16:24 評論於
Review speed: 2.0 | Submission hit rate: 50.0 Emphasized research direction: circRNA; tumors; tumor biology Experience sharing: Well, what's the point if your article can't get funded by NSFC even if it's scored 40 or 60? The current situation of the mc is that its reputation within the industry is declining. Although there are some decent articles, the overall approach is conventional and non-coding. Is it true that tumors are only non-coding? In today's situation, the influence of journals lies not only in the Impact Factor but also in the hearts of scientific researchers. To be honest, looking at the journals for grant applications, two mcs are really not as useful as one Cancer Research. Not to mention the old top journals like EMBO, PNAS, and JCI. If you really want to do serious research, it's better to submit to NCS sub-journals or well-known tumor journals
(0) 讚! | 元魁来了

作者: Edison Springhall


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-29 12:31:52 評論於
Thank you
(0) 讚! | Edison Springhall

作者: 四象天晴


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-27 21:17:34 評論於
Please translate the following passage into English and Japanese
(0) 讚! | 四象天晴

作者: 东海书蝶


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-26 16:01:00 評論於
Rejected for three days
(0) 讚! | 东海书蝶

作者: Edison Springhall


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-24 21:25:39 評論於
Do you know how many reviewers are needed for the first review? How long does it take for the reviewers to return their feedback after being invited?
(0) 讚! | Edison Springhall

作者: Edison Springhall


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-24 17:06:35 評論於
Hello, are there two reviewers for the first review? How long will it take to receive their feedback?
(0) 讚! | Edison Springhall

作者: Edison Springhall


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-24 16:03:00 評論於
Hello, how many reviewers are there in the first round of review?
(0) 讚! | Edison Springhall

作者: Edison Springhall


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-24 15:40:09 評論於
Hello, a few reviewers after submission
(0) 讚! | Edison Springhall

作者: Edison Springhall


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-24 12:32:04 評論於
Hello, how many reviewers are there after the submission?
(0) 讚! | Edison Springhall

作者: Edison Springhall


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-24 10:51:17 評論於
Hello, may I ask how many reviewers are responsible for reviewing this magazine?
(0) 讚! | Edison Springhall

作者: Edison Springhall


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-24 10:25:39 評論於
Hello, how many reviewers are there for the first review, and how long does it usually take to receive feedback?
(0) 讚! | Edison Springhall

首頁    上一頁    4    5    6    7    8    9    10    下一頁    末頁  (頁
/40)

開始撰寫 [Molecular Cancer] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*